Clinical potential of meningioma genomic insights: a practical review for neurosurgeons

Neurosurgical Focus
Michael KarsyD Ryan Ormond

Abstract

Meningiomas are among the most common intracranial pathological conditions, accounting for 36% of intracranial lesions treated by neurosurgeons. Although the majority of these lesions are benign, the classical categorization of tumors by histological type or World Health Organization (WHO) grade has not fully captured the potential for meningioma progression and recurrence. Many targeted treatments have failed to generate a long-lasting effect on these tumors. Recently, several seminal studies evaluating the genomics of intracranial meningiomas have rapidly changed the understanding of the disease. The importance of NF2 (neurofibromin 2), TRAF7 (tumor necrosis factor [TNF] receptor-associated factor 7), KLF4 (Kruppel-like factor 4), AKT1, SMO (smoothened), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), and POLR2 (RNA polymerase II subunit A) demonstrates that there are at least 6 distinct mutational classes of meningiomas. In addition, 6 methylation classes of meningioma have been appreciated, enabling improved prediction of prognosis compared with traditional WHO grades. Genomic studies have shed light on the nature of recurrent meningioma, distinct intracranial locations and mutational patter...Continue Reading

References

Dec 16, 2004·Proceedings of the National Academy of Sciences of the United States of America·Rong RongKeqiang Ye
Jan 10, 2006·Neurosurgical Focus·Brian T Ragel, Randy L Jensen
Sep 15, 2010·Journal of Neuro-oncology·Brian T Ragel, Randy L Jensen
Mar 20, 2012·Molecular Cancer Research : MCR·Marianne F JamesVijaya Ramesh
Jan 22, 2013·Nature Genetics·Priscilla K BrastianosRameen Beroukhim
Jan 16, 2016·Journal of Neurosurgery·Wenya Linda BiIan F Dunn
Jan 31, 2016·Neuro-oncology·Malak AbedalthagafiSandro Santagata
Mar 26, 2016·Neurosurgery Clinics of North America·Mark S ShiroishiChia-Shang J Liu
Mar 26, 2016·Neurosurgery Clinics of North America·Michael KarsyRandy L Jensen
Aug 23, 2016·Nature Genetics·Victoria E ClarkMurat Günel
Sep 7, 2016·The Lancet Oncology·Roland GoldbrunnerMichael Weller
Jul 18, 2017·NPJ Genomic Medicine·Wenya Linda BiRameen Beroukhim
Nov 18, 2017·PloS One·Thibaud P CorollerHugo J W L Aerts
Jan 6, 2018·Nature Reviews. Neurology·Matthias PreusserChristian Mawrin

❮ Previous
Next ❯

Citations

May 2, 2019·Acta Neuropathologica Communications·Angela N ViaeneNadia Dahmane
Sep 26, 2020·Frontiers in Oncology·Lianhua ZhaoZaiyu Guo
Oct 9, 2018·Frontiers in Immunology·Sining ZhuPing Xie
Nov 3, 2020·Current Neurology and Neuroscience Reports·Pedro David Delgado-LópezJavier Martín-Alonso
Jan 16, 2021·International Journal of Molecular Sciences·Suha BachirSoma Sengupta
Jun 3, 2021·Cancers·Paul E ConstanthinTorstein R Meling
Aug 6, 2021·Journal of Neuro-oncology·Lan JinJennifer Moliterno

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping
exome sequencing
chip

Clinical Trials Mentioned

NCT02523014
NCT03071874
NCT02831257
NCT02648997
NCT03173950
NCT03279692

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.